All In Biotech

Drug Trial Radar · NCT07761572

CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Feb 2, 2029

Study completion Apr 30, 2029

Sponsor

Lead sponsor
Cereno Scientific ABIndustry
Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • CS1Drug

    160 mg delayed release capsules taken orally once daily in the evening

  • PlaceboDrug

    Matching placebo capsules taken orally once daily in the evening

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pulmonary vascular resistance (PVR)Time frame: Baseline to Week 36

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.